SGLT2 inhibitors lowered glycated hemoglobin by 0.46 percent when compared to a placebo, and this blood glucose reduction was connected to a lower risk of all fatal and non-fatal events except stroke [104]. This evidence concerns the gene SLC5A2 and Stroke.